NR4A1 and breast carcinoma: We investigated the association of computed tomography (CT)‐derived body composition indices with therapeutic responses in patients with hormone receptor‐positive, HER2‐negative advanced breast cancer (ABC) on endocrine plus CDK4/6 inhibitor (CDK4/6i) treatment.